Combinations of beta -3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder

一种膀胱过度、肾上腺素的技术，应用在治疗与膀胱过度活动症有关的一种或多种症状,夜尿和尿失禁)领域，能够解决不能充分地治疗急迫性等问题

Active Publication Date: 2013-08-28
B3AR THERAPEUTICS INC
View PDF11 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, existing medications do not adequately treat urgency, one of the most distressing symptoms of OAB

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations of beta -3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
  • Combinations of beta -3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
  • Combinations of beta -3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0107] As used herein, the symbols and conventions used in these Methods, Schemes and Examples are consistent with those used in contemporary scientific literature such as the Journal of the American Chemical Society and the Journal of Biological Chemistry. All starting materials were obtained from commercial suppliers and used without further purification unless otherwise stated. In particular, the following abbreviations may be used in the examples and throughout the specification:

[0108]

[0109] 1. Drug interaction studies using healthy human patients

[0110] Drug interaction studies were conducted in healthy human volunteers using repeated oral doses of solaburone and oxybutynin administered alone or in combination with each other to evaluate the effects on pharmacokinetic and pharmacodynamic parameters, As measured by residual urine volume (post-void residual volume, PVR). PVR is measured at steady state in subjects treated with each agent alone as well as in com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application No. 61 / 370,171 filed August 3, 2010 under 35 U.S.C. §119(e), the entire contents of which are incorporated herein by reference. field of invention [0003] The present invention relates to pharmaceutical combinations and methods of use thereof. In particular, the present invention relates to a pharmaceutical combination comprising a beta-3 adrenergic receptor agonist and a muscarinic acetylcholine receptor antagonist (hereinafter referred to as 'muscarinic receptor antagonist'), and the use of such a combination Methods for treating one or more symptoms associated with overactive bladder, such as frequency of urgency, nocturia, and urinary incontinence. Background of the invention [0004] The International Continence Society (ICS) defines overactive bladder (OAB) as an acute syndrome with or without urge incontinence accompanied by frequent urination and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K31/216A61P13/10
CPCA61K31/137A61K31/216A61K45/06A61P13/00A61P13/02A61P13/10A61P43/00A61K2300/00
Inventor 斯蒂芬·卡尔塔比亚诺埃利奥特·奥尔施泰因斯图尔特·麦卡勒姆
Owner B3AR THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap